Physician profile

George Barros

Pulmonary Disease · Pembroke Pines, FL

NPI 1740214451

$1,869.45

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$862.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $980.92 2019-2024 Trelegy Ellipta, Arexvy
Abbott Laboratories $398.72 2024 Gallant, Aveir
Philips North America LLC $104.40 2019-2021
Daiichi Sankyo INC. $98.58 2021
Astrazeneca Pharmaceuticals LP $95.90 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $74.32 2019-2022
Genentech USA, INC. $65.47 2019
Mallinckrodt Hospital Products INC. $19.03 2022
Circassia INC. $17.11 2019
Mylan Specialty L.P. $15.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George Barros

$1,869.45

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/782983/george-barros

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.